Search

Clinical Trials

Sonodynamic Therapy in Patients With Recurrent GBM (GBM 001)

Patients diagnosed with glioblastoma (GBM) are faced with limited treatment options. This pilot study will evaluate the safety and feasibility of combining an investigational drug called 5-ALA with neuronavigation-guided low-intensity focused ultrasound (LIFU) for patients who have recurrent GBM. Focused ultrasound (FUS) can be used to non-invasively destroy tumor tissue while preserving normal tissue. When FUS is combined with 5-ALA, this combinatorial approach is called sonodynamic therapy (SDT), and this investigational therapy is being tested for its ability to cause damage to GBM cells. SDT will take place prior to surgery for recurrent GBM.

Contact: Zachary Sturgill; 434-243-9986; mailto:FFM7RC@uvahealth.org

Principal Investigator: Shayan Moosa, MD

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma (Mel 70)

Status: Active, recruiting

This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment that uses ultrasound waves to heat and destroy tumor tissue, and an injection in the tumor with an experimental drug that activates the immune system called polyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine). Neither the drug nor the device that are used in this study have been approved by the U.S. Food and Drug Administration (FDA).

Contact: Olena Glushakova; 434-409-6206; mailto:OYG2N at uvahealth.org

Principal Investigator: Lynn Dengel, MD

Focused Ultrasound and Gemcitabine in Breast Cancer (Breast 54)

Status: Active, recruiting

This study tests the use of focused ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in patients with early-stage breast cancers. We are testing the effects of each of these regimens on cells in the immune system. We hypothesize that the combination of focused ultrasound ablation and gemcitabine will decrease myeloid-derived suppressor cells and will increase T cell activity. We also hypothesize that focused ultrasound ablation and low-dose gemcitabine will be safe and will result in non-inferior surgical completion rates and tumor margin assessments.

Contact: Olena Glushakova; 434-409-6206; mailto:OYG2N at uvahealth.org

Principal Investigator: Patrick Dillon, MD

Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48)

Status: Completed

This pilot study evaluates the use of focused ultrasound combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after focused ultrasound and one-half of participants will be randomized to receive their first dose of pembrolizumab before focused ultrasound.

Principal Investigator: Patrick Dillon, MD

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

Status: Completed

This is a prospective, multi-center, single-arm study to establish the safety and feasibility of BBB (blood brain barrier) disruption along the periphery of tumor resection cavity using the ExAblate Neuro Model 4000 Type 2 (220 kHz) system. For this study, patients will be eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be eligible for enrollment.